endometrial cancer
Oncology · 2022–2025
7decisions
3medicines
7carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| pembrolizumab Primary advanced or recurrent endometrial cancer, regardless of mismatch repair (MMR) status, in combination with platinum-based chemotherapy followed by… | Jul 2025 | Not recommended | input received Medical Oncology Group |
| dostarlimab Treatment of primary advanced or first recurrent mismatch repair proficient (pMMR) endometrial cancer in combination with carboplatin and paclitaxel, in… | May 2025 | Not recommended | input received Medical Oncology Group · Inherited Cancers Australia · Rare Cancers Australia |
| durvalumab, olaparib Advanced, metastatic or recurrent endometrial cancer (dMMR population receiving durvalumab + platinum-based chemotherapy followed by maintenance durvalumab… | Nov 2024 | Recommended with restriction | input received Rare Cancers Australia |
| dostarlimab Treatment of recurrent or advanced mismatch repair deficient (dMMR) endometrial cancer that has progressed on or following prior treatment with a… | Mar 2023 | Recommended with restriction | input received Rare Cancers Australia |
| pembrolizumab Advanced endometrial cancer with disease progression following prior systemic therapy. Requested as monotherapy for deficient DNA mismatch repair (dMMR)… | Mar 2023 | Recommended with restriction | input received |
| dostarlimab Treatment of primary advanced or first recurrent endometrial cancer (dMMR population) in combination with platinum-containing chemotherapy. The submission… | Nov 2023 | Recommended with restriction | input received Rare Cancers Australia |
| dostarlimab Advanced or recurrent mismatch repair deficient (dMMR) endometrial cancer that has progressed on or following prior treatment with a platinum-containing… | Mar 2022 | Not recommended | input received Medical Oncology Group |
Who spoke
Rare Cancers Australia · Medical Oncology Group · Inherited Cancers Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 7 of 7 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.